Implementation and Resource Optimization of an Oral Anti-Cancer Medication Clinical Pharmacy Trainee Program: Operational and Financial Impact at a Tertiary Cancer Centre

1. Introduction

The landscape of oncology therapeutics has drastically evolved, marked by an exponential increase in the indications and utilization of oral anticancer medications (OAMs) [1]. This paradigm shift transitions complex monitoring requirements from traditional inpatient or ambulatory infusion suites directly into patients' homes, substantially increasing the operational burden on ambulatory oncology specialty pharmacies to provide robust clinical pharmacy services (OAM CPS) [1,2]. These services—critical to preventing treatment failures, managing toxicities, and avoiding unnecessary treatment interruptions—include proactive clinical charting, side-effect triage and management, drug-drug interaction (DDI) screening, and adherence evaluations [2].

Despite the clear imperative for specialized clinical oversight, systemic educational gaps persist across the Canadian pharmacy landscape (Figure 1). National cross-sectional surveys spearheaded by Canadian oncology pharmacy investigators reveal that fewer than 14% of practising pharmacists feel they received adequate oncology education during their undergraduate or professional degree programs [3]. While advanced experiential pharmacy students have been shown to successfully expand patient capacity and document high-volume interventions across general ambulatory care clinics [4], these frameworks are historically under-reported within high-acuity, specialized oncology environments.

Safety-focused student frameworks have seen historic success in standardizing multi-site outcomes and delivering quantified cost-avoidance across community and institutional care configurations [5,6]. However, an expanding cohort of OAM-naive pharmacy students continue to enter the healthcare system poorly equipped to manage complex oral oncology care independently [2]. Given the constraints on modern healthcare budgets and rising cancer incidence, expanding specialized clinical pharmacy human resources through traditional hiring models is difficult to execute sustainably [2].

To overcome this dual operational and educational bottleneck, the Sunnybrook Odette Cancer Centre Pharmacy (SOCCP) designed and implemented the Oral Anticancer Medication Clinical Co-op Program (OAMCCP). The primary goal of this pharmacist-led framework was to establish a unique, high-value, practice-based learning pathway for pharmacy students while strategically adding operational capacity to the specialty pharmacy workflow at a fraction of standard payroll costs, without compromising clinical quality or patient safety.

2. Materials and Methods

The institutional OAMCCP was formally launched in the fall semester of 2022. The operational design relied on onboarding one PharmD co-op student from the University of Waterloo School of Pharmacy per sequential 16-week academic term to work full-time alongside the core SOCCP OAM team.

A rigorous onboarding process prepared students to execute an array of clinical pharmacy duties under direct pharmacist supervision. To align our service evaluations with national benchmarking trends, student activities were structurally mapped to established Canadian ambulatory oncology clinical pharmacy key performance indicators (AOcpKPIs) [2]. To preserve clinical accuracy and patient safety, the institutional safety mandate was applied wherein 100% of student assessments, documentations, and clinical recommendations were reviewed, validated, and co-signed by a fully licensed ambulatory oncology specialty pharmacist prior to implementation. Under this framework, student duties included:

• • Initial Interventions (AOcpKPI-aligned): Conducting Best Possible Medication Histories (BPMH) and comprehensive DDI evaluations at baseline therapy initiation.
• • Patient Education & Support (AOcpKPI-aligned): Providing initial therapeutic and supportive care counseling, alongside reactive and proactive tele-health symptom monitoring and management.
• • Adherence & Clinical Assessment (AOcpKPI-aligned): Screening for drug-therapy problems (DTPs) linked to toxicity and treatment adherence.
• • Quality Assurance Operations: Facilitating clinical program tracking through predefined administrative bundles, including patient roster upkeep (QA Bundle #1) and administrative documentation for specialized exceptional drug access programs (QA Bundle #2).

Program impact was captured prospectively using a mixed-methods design across four performance indicators: quantitative workload data tracking over 15 weeks, direct institutional payroll expenditure analysis comparing student and pharmacist compensation, standardized post-consultation patient satisfaction surveys on a 1–10 point Likert scale, and qualitative trainee reflection portfolios

Generative artificial intelligence (Gemini 1.5 Pro, Google) to refine the language, improve readability, and assist with formatting the manuscript and references. The final text was fully reviewed, revised, and validated by the authors, who maintain complete accountability for the manuscript's intellectual content.

3. Results

3.1. Workload and Service Capacity Analysis

During a representative 15-week observational window, the clinical co-op student independently completed a cumulative total of 673 specialized tasks, averaging 56.1 individual interventions every week. A breakdown of specific tasks, hours invested, and estimated FTE equivalence is provided in Table 1. Proactive telephone follow-ups (214 completed interventions) and deep clinical chart reviews (279 completed interventions) consumed the largest portion of student time, accounting for an aggregate 8.7 hours and 3.9 hours per week respectively. Cumulatively, the trainee contributed an average of 19.2 hours of direct clinical support weekly, establishing a +0.5 FTE increase in real-time pharmacy department service capacity.

3.2. Patient Satisfaction Evaluation

A cross-sectional cohort of 29 outpatients undergoing clinical management for multiple oncological agents (including lenvatinib, darolutamide, olaparib, and lenalidomide) completed satisfaction evaluations (Table 2). The mean clinical pharmacy service satisfaction score across the cohort was 9.6 out of 10. Crucially, the embedded co-op student independently and satisfactorily managed all treatment-related questions for 28 out of the 29 survey participants (97%), with immediate backend validation by the supervising pharmacist, indicating that service quality matched institutional standards.During a representative 15-week observational window, the clinical co-op student independently completed a cumulative total of 673 specialized tasks, averaging 56.1 individual interventions every week. A breakdown of specific tasks, hours invested, and estimated FTE equivalence is provided in Table 1. Proactive telephone follow-ups (214 completed interventions) and deep clinical chart reviews (279 completed interventions) consumed the largest portion of student time, accounting for an aggregate 8.7 hours and 3.9 hours per week respectively. Cumulatively, the trainee contributed an average of 19.2 hours of direct clinical support weekly, establishing a +0.5 FTE increase in real-time pharmacy department service capacity.

3.3. Economic Utility Analysis

Financial comparison highlighted a highly favorable health-system economic outlook. Maintaining a full-time (1.0 FTE) clinical co-op student requires a fixed operational payroll cost of approximately $44,700 per annum. Given that the student absorbed workload equivalent to 0.5 FTE of a fully licensed ambulatory clinical oncology pharmacist—valued at an annual institutional baseline salary of $80,600 for a 0.5 FTE portion—the model allowed the specialty care center to capture essential clinical hours for a fraction of traditional expenditures ($44,700 for PharmD student 1.0 FTE / $80,600 for Pharmacist 0.5 FTE = 55%).

3.4. Educational Value and Trainee Feedback

Qualitative assessment of post-rotation portfolios reflected an accelerated acquisition of complex professional knowledge. Trainees consistently emphasized that the immersive framework successfully bridged gaps in didactic pharmacy education. Key longitudinal reflections are provided in Figure 2.

4. Discussion

This evaluation demonstrates that the integration of a structured, specialized clinical co-op student model into an ambulatory oncology specialty pharmacy effectively mitigates systemic capacity challenges without increasing operational costs or compromising patient care. Findings suggest the student successfully generated an additional 0.5 FTE of clinical capacity at a fraction of the cost. By taking on time-intensive processes like chart preparation, routine documentation, and tele-health follow-ups, the co-op student allowed the senior pharmacy staff to optimize their focus on advanced drug therapy problems and high-acuity interventions.

The substantial volume of student interventions captured in this pilot (56.1 tasks/week) strongly aligns with ambulatory experiential literature. Our findings expand upon the baseline work of Patel et al. (2016), who demonstrated that structured student integrations efficiently drive foundational ambulatory care indicators like medication reconciliation and therapeutic education [4]. In a foundational multi-year analysis, Shepler (2014) validated that pharmacy students on advanced rotations generate monumental interventions that correlate directly to quantified cost-savings, averaging $148 per documented intervention [5]. Similarly, Tualla et al. (2019) demonstrated that embedding senior trainees within ambulatory and community clinics yields major clinical and economic value through proactive toxicity screening and adverse event prevention [6]. Our model corroborates these findings within a highly specialized tertiary oncology environment, providing concrete financial metrics demonstrating that a 1.0 FTE student captures clinical hours valued at $80,600/year for a minimal payroll cost of $44,700 (~45% cost savings).

Importantly, the high patient satisfaction ratings show that introducing a learner into the care pathway did not disrupt the quality of the clinical services. Patients received timely, high-touch phone outreach that an otherwise resource-constrained staff might struggle to deliver consistently [2]. A paramount consideration of this program's operational viability is its adherence to stringent patient safety protocols. While the co-op trainee absorbed a significant operational burden, 100% of clinical data compilation, documentation, and patient outreach logs were scrutinized and verified by a licensed oncology pharmacist. This tiered supervision model guarantees that patient care standards are never minimized; rather, safety is augmented through an extra layer of active clinical screening.

Furthermore, this framework directly addresses the severe lack of undergraduate oncology education identified across the Canadian pharmacy landscape [3]. To elevate our tracking from basic task-counting to high-value care, student duties were aligned with established clinical pharmacy key performance indicators (cpKPIs). As emphasized by Lo et al. (2016), true institutional benchmarking must shift from pure workload metrics to discrete process measures explicitly linked to positive patient outcomes, such as formal BPMH, DDI screening, and collaborative care plans [7]. Global review data indicates that while 85.8% of current pharmacy KPIs remain process-based, there is a historical lack of published reference values within specialty ambulatory settings [8]. By utilizing and reporting these explicit reference values under an OAM-specific framework, our program establishes a highly transparent, safety-validated blueprint for workforce planning and institutional resource justification.

5. Conclusions

The Oral Anticancer Medication Clinical Co-op Program is an effective, pharmacist-led strategy that bridges experiential education gaps, expands clinical care capacity by 0.5 FTE, and maintains excellent patient satisfaction while optimizing institutional expenditures. Backed by strict pharmacist verification pathways and aligned with contemporary national quality metrics, this operational model serves as a safe and practical blueprint for specialty oncology pharmacies looking to scale their clinical services amidst rising demands and limited resource allocations.